ROS and MiRNA Dysregulation in Ovarian Cancer Development, Angiogenesis and Therapeutic Resistance

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Jun 24

PMID 35743145

Authors

David C Stieg

Yifang Wang

Ling-Zhi Liu

Bing-Hua Jiang

Affiliations

Soon will be listed here.

Abstract

The diverse repertoires of cellular mechanisms that progress certain cancer types are being uncovered by recent research and leading to more effective treatment options. Ovarian cancer (OC) is among the most difficult cancers to treat. OC has limited treatment options, especially for patients diagnosed with late-stage OC. The dysregulation of miRNAs in OC plays a significant role in tumorigenesis through the alteration of a multitude of molecular processes. The development of OC can also be due to the utilization of endogenously derived reactive oxygen species (ROS) by activating signaling pathways such as PI3K/AKT and MAPK. Both miRNAs and ROS are involved in regulating OC angiogenesis through mediating multiple angiogenic factors such as hypoxia-induced factor (HIF-1) and vascular endothelial growth factor (VEGF). The NAPDH oxidase subunit NOX4 plays an important role in inducing endogenous ROS production in OC. This review will discuss several important miRNAs, NOX4, and ROS, which contribute to therapeutic resistance in OC, highlighting the effective therapeutic potential of OC through these mechanisms.

Citing Articles

Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux.

Zhang Y, Qiu J, Wang W, Sun F, Wang X, Liu W Exp Hematol Oncol. 2025; 14(1):21.

PMID: 40012003 PMC: 11866804. DOI: 10.1186/s40164-025-00620-z.

Exploring Strategies to Prevent and Treat Ovarian Cancer in Terms of Oxidative Stress and Antioxidants.

Long Y, Shi H, Ye J, Qi X Antioxidants (Basel). 2025; 14(1).

PMID: 39857448 PMC: 11762571. DOI: 10.3390/antiox14010114.

Cucurbitacin E elicits apoptosis in laryngeal squamous cell carcinoma by enhancing reactive oxygen species-regulated mitochondrial dysfunction and endoplasmic reticulum stress.

Zheng X, Tang P, Li H, Ye T, Zhu X, He W Am J Cancer Res. 2024; 14(8):3905-3921.

PMID: 39267666 PMC: 11387858. DOI: 10.62347/HPQQ9412.

Research progress in endometriosis-associated ovarian cancer.

Tang L, Bian C Front Oncol. 2024; 14:1381244.

PMID: 38725626 PMC: 11079782. DOI: 10.3389/fonc.2024.1381244.

Spotlight on New Hallmarks of Drug-Resistance towards Personalized Care for Epithelial Ovarian Cancer.

Frezzini S, Lonardi S Cells. 2024; 13(7.

PMID: 38607050 PMC: 11011744. DOI: 10.3390/cells13070611.

References

Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat F . Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A. 2010; 107(15):6982-7. PMC: 2872463. DOI: 10.1073/pnas.1002472107. View

An Y, Yang Q . MiR-21 modulates the polarization of macrophages and increases the effects of M2 macrophages on promoting the chemoresistance of ovarian cancer. Life Sci. 2019; 242:117162. DOI: 10.1016/j.lfs.2019.117162. View

Aagaard L, Rossi J . RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev. 2007; 59(2-3):75-86. PMC: 1978219. DOI: 10.1016/j.addr.2007.03.005. View

Bookman M, Brady M, McGuire W, Harper P, Alberts D, Friedlander M . Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009; 27(9):1419-25. PMC: 2668552. DOI: 10.1200/JCO.2008.19.1684. View

Shih I, Kurman R . Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004; 164(5):1511-8. PMC: 1615664. DOI: 10.1016/s0002-9440(10)63708-x. View

Yang H, Villani R, Wang H, Simpson M, Roberts M, Tang M . The role of cellular reactive oxygen species in cancer chemotherapy. J Exp Clin Cancer Res. 2018; 37(1):266. PMC: 6211502. DOI: 10.1186/s13046-018-0909-x. View

Liew P, Hsu C, Liu W, Lee Y, Lee Y, Chen C . Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma. Int J Clin Exp Pathol. 2015; 8(5):5642-9. PMC: 4503147. View

Mizuno T, Kojima Y, Yonemori K, Yoshida H, Sugiura Y, Ohtake Y . Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer. Oncol Lett. 2020; 20(6):336. PMC: 7583842. DOI: 10.3892/ol.2020.12200. View

Witham J, Valenti M, De-Haven-Brandon A, Vidot S, Eccles S, Kaye S . The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res. 2007; 13(23):7191-8. DOI: 10.1158/1078-0432.CCR-07-0362. View

10.

Forsythe J, Jiang B, Iyer N, Agani F, Leung S, Koos R . Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996; 16(9):4604-13. PMC: 231459. DOI: 10.1128/MCB.16.9.4604. View

11.

Jansson M, Lund A . MicroRNA and cancer. Mol Oncol. 2012; 6(6):590-610. PMC: 5528350. DOI: 10.1016/j.molonc.2012.09.006. View

12.

Chung Y, Kim S, Hong J, Lee J, Lee N, Lee Y . Overexpression of HER2/HER3 and clinical feature of ovarian cancer. J Gynecol Oncol. 2019; 30(5):e75. PMC: 6658608. DOI: 10.3802/jgo.2019.30.e75. View

13.

Martinez M, Andriantsitohaina R . Reactive nitrogen species: molecular mechanisms and potential significance in health and disease. Antioxid Redox Signal. 2008; 11(3):669-702. DOI: 10.1089/ars.2007.1993. View

14.

Grauers Wiktorin H, Nilsson T, Aydin E, Hellstrand K, Palmqvist L, Martner A . Role of NOX2 for leukaemic expansion in a murine model of BCR-ABL1 leukaemia. Br J Haematol. 2017; 182(2):290-294. DOI: 10.1111/bjh.14772. View

15.

le Sage C, Nagel R, Egan D, Schrier M, Mesman E, Mangiola A . Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007; 26(15):3699-708. PMC: 1949005. DOI: 10.1038/sj.emboj.7601790. View

16.

Van Houten B, Woshner V, Santos J . Role of mitochondrial DNA in toxic responses to oxidative stress. DNA Repair (Amst). 2005; 5(2):145-52. DOI: 10.1016/j.dnarep.2005.03.002. View

17.

Ray P, Huang B, Tsuji Y . Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal. 2012; 24(5):981-90. PMC: 3454471. DOI: 10.1016/j.cellsig.2012.01.008. View

18.

Li J, Zheng C, Wang M, Umano A, Dai Q, Zhang C . ROS-regulated phosphorylation of ITPKB by CAMK2G drives cisplatin resistance in ovarian cancer. Oncogene. 2022; 41(8):1114-1128. DOI: 10.1038/s41388-021-02149-x. View

19.

Kajla S, Mondol A, Nagasawa A, Zhang Y, Kato M, Matsuno K . A crucial role for Nox 1 in redox-dependent regulation of Wnt-β-catenin signaling. FASEB J. 2012; 26(5):2049-59. DOI: 10.1096/fj.11-196360. View

20.

van Jaarsveld M, Helleman J, Boersma A, van Kuijk P, van Ijcken W, Despierre E . miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene. 2012; 32(36):4284-93. DOI: 10.1038/onc.2012.433. View